tiprankstipranks
Trending News
More News >
Venus Medtech (Hangzhou), Inc. Class H (HK:2500)
:2500
Hong Kong Market

Venus Medtech (Hangzhou), Inc. Class H (2500) AI Stock Analysis

Compare
0 Followers

Top Page

HK

Venus Medtech (Hangzhou), Inc. Class H

(2500)

Rating:50Neutral
Price Target:
HK$2.50
▼(-4.58%Downside)
The overall stock score reflects significant financial challenges, with persistent losses and weak cash flow generation weighing heavily. Technical analysis provides a slightly more positive outlook with some short-term stability, but the valuation remains a concern given the negative P/E ratio and lack of dividend yield. Without earnings call data or corporate events to influence the score, the stock's outlook remains cautious.

Venus Medtech (Hangzhou), Inc. Class H (2500) vs. iShares MSCI Hong Kong ETF (EWH)

Venus Medtech (Hangzhou), Inc. Class H Business Overview & Revenue Model

Company DescriptionVenus Medtech (Hangzhou), Inc. Class H (2500) is a leading Chinese medical device company specializing in the research, development, and commercialization of minimally invasive interventional medical devices. The company primarily focuses on innovative solutions for structural heart diseases, providing a range of products that address the needs of patients with conditions such as aortic valve stenosis and mitral regurgitation. With a commitment to improving patient outcomes, Venus Medtech leverages cutting-edge technology to enhance the quality of life for patients globally.
How the Company Makes MoneyVenus Medtech generates revenue through the sale of its medical devices designed for the treatment of structural heart diseases. The company's key revenue streams include the commercialization of transcatheter heart valve systems, such as the Venus A-Valve and Venus P-Valve, which are used to treat aortic and pulmonary valve stenosis, respectively. Additionally, the company invests in research and development to innovate new products and improve existing ones, thus maintaining a competitive edge in the market. Strategic partnerships and collaborations with healthcare providers, hospitals, and international distributors also play a significant role in expanding their market reach and driving sales. Regulatory approvals in various regions further bolster their ability to penetrate new markets and increase revenue.

Venus Medtech (Hangzhou), Inc. Class H Financial Statement Overview

Summary
Venus Medtech faces substantial financial challenges with persistent losses and cash flow difficulties. Despite a strong gross profit margin and manageable debt levels, the inability to achieve profitability and positive cash flow raises significant concerns about long-term sustainability.
Income Statement
35
Negative
The company exhibits a challenging financial situation with consistent net losses over the years. The gross profit margin is relatively strong, indicating effective cost management, but the company is struggling with negative EBIT and EBITDA margins, reflecting significant operational challenges. Revenue growth has been inconsistent, with a decline in the most recent year, highlighting potential issues in market expansion or product demand.
Balance Sheet
55
Neutral
The balance sheet shows a strong equity position with a manageable level of debt, as reflected by a favorable debt-to-equity ratio. However, the declining equity ratio over the years and consistent net losses pose risks to financial stability. The company has maintained a solid cash position, but the reduction in cash and equivalents suggests potential liquidity concerns if losses persist.
Cash Flow
45
Neutral
Cash flow analysis reveals significant challenges with negative free cash flow over multiple periods, although there is a positive shift in operating cash flow in the latest year. The operating cash flow to net income ratio indicates some improvement, but the company's cash flow generation remains weak overall, raising concerns about its ability to sustain operations without additional financing.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue470.83M491.37M406.46M415.86M276.05M
Gross Profit367.75M389.20M314.00M324.34M227.28M
EBITDA-612.96M-547.84M-999.37M-324.03M-152.83M
Net Income-714.31M-703.75M-1.12B-371.39M-182.87M
Balance Sheet
Total Assets3.25B4.41B5.28B5.11B4.32B
Cash, Cash Equivalents and Short-Term Investments305.70M781.64M1.88B2.96B2.75B
Total Debt369.09M826.19M899.64M70.78M32.76M
Total Liabilities1.04B1.49B1.65B477.61M461.19M
Stockholders Equity2.21B2.92B3.61B4.55B3.82B
Cash Flow
Free Cash Flow-17.82M-872.93M-908.23M-602.08M-361.05M
Operating Cash Flow23.74M-610.02M-729.46M-456.92M-237.00M
Investing Cash Flow-19.90M-346.86M-1.07B-653.04M-297.94M
Financing Cash Flow-487.34M-173.99M635.14M1.39B927.75M

Venus Medtech (Hangzhou), Inc. Class H Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.62
Price Trends
50DMA
2.55
Positive
100DMA
3.36
Negative
200DMA
4.49
Negative
Market Momentum
MACD
0.02
Positive
RSI
49.84
Neutral
STOCH
32.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2500, the sentiment is Negative. The current price of 2.62 is above the 20-day moving average (MA) of 2.62, above the 50-day MA of 2.55, and below the 200-day MA of 4.49, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.84 is Neutral, neither overbought nor oversold. The STOCH value of 32.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2500.

Venus Medtech (Hangzhou), Inc. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
€6.82B61.893.22%45.82%
60
Neutral
HK$1.46B-1.28%17.45%85.71%
60
Neutral
HK$15.14B5.56-7.43%4.30%11.60%-21.06%
52
Neutral
HK$1.08B-8.64%-20.99%45.74%
51
Neutral
€4.27B-10.43%36.76%42.89%
50
Neutral
HK$1.16B-27.82%-6.12%0.43%
47
Neutral
HK$2.12B-2.19%5.32%89.43%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.58
-3.04
-54.09%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
37.55
21.35
131.79%
HK:2216
Broncus Holding Corp.
2.05
1.46
247.46%
HK:2160
MicroPort CardioFlow Medtech Corp.
0.89
0.05
5.95%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
20.80
10.56
103.11%
HK:9996
Peijia Medical Ltd.
6.47
4.19
183.77%

Venus Medtech (Hangzhou), Inc. Class H Corporate Events

Venus Medtech Announces Successful AGM Resolutions
Jun 27, 2025

Venus Medtech (Hangzhou) Inc. announced that all resolutions proposed at its 2024 Annual General Meeting (AGM) were approved. The AGM, held on June 27, 2025, included the election of a new chairman and board members, re-appointment of auditors, and approval of the 2024 annual report and profit distribution plan. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued governance and operational stability.

Venus Medtech Announces Board Composition and Roles
Jun 27, 2025

Venus Medtech (Hangzhou) Inc. has announced the composition of its board of directors and their respective roles within various board committees. This update reflects the company’s commitment to strong corporate governance and strategic leadership, which is crucial for maintaining its competitive position in the medical technology sector.

Venus Medtech Enhances Governance with New Nomination Committee Terms
Jun 27, 2025

Venus Medtech (Hangzhou) Inc. has outlined the terms of reference for its Nomination Committee, a specialized committee under the Board of Directors. The committee, consisting of at least three directors with a majority of independent non-executive directors, is tasked with ensuring diversity and suitable qualifications in board member selection. This initiative is expected to enhance the company’s governance structure and align with its corporate strategy, potentially impacting its industry positioning by promoting a diverse and skilled leadership team.

Venus Medtech Announces 2024 AGM with Key Resolutions
Jun 5, 2025

Venus Medtech (Hangzhou) Inc. has announced its 2024 Annual General Meeting scheduled for June 27, 2025, where key resolutions will be discussed and approved. These include the approval of the 2024 annual report, re-election of directors, appointment of auditors, and granting mandates for share issuance and repurchase, reflecting the company’s ongoing strategic management and governance efforts.

Venus Medtech Announces Board and Supervisory Committee Re-Elections
May 30, 2025

Venus Medtech (Hangzhou) Inc. has announced the proposed re-election and appointment of directors and supervisors for the third session of its Board and Supervisory Committee. The company plans to re-elect and appoint a total of eight directors and three supervisors, with the re-election proposal set to be approved at the 2024 annual general meeting. This strategic move is expected to ensure continuity in leadership and governance, potentially impacting the company’s operational stability and stakeholder confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 28, 2025